Skip to main content
OpenTrials
Completed

NCT Number: NCT07660536

To Study the Efficacy and Safety of Doxercalciferol on Spinal and Femoral Density in Postmenopausal Osteopenic Women in a Long Term 2 Year Study

A clinical trial to compare the effect of doxercalciferol or placebo in preventing bone loss from the spine and femur in postmenopausal women

Completed

Looking for future studies?

Notify Me

Key information

Age range

60 year–78 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Creighton University Medical center

Omaha, Nebraska, 68132, United States

About this study

A double blind study of a new type of vitamin D ,named doxercalciferol ( 1α hydroxyvitamin D2) or placebo is given to study its effect on preventing and treating osteoporosis.The trial was a pilot study for one year that was extended to a second year . We used Dual energy Xray absorptiometry (DEXA) to measure bone density of the spine and proximal femur every 6 months.Safety of the drug was monitored by measuring blood and urine calcium frequently.

The study group was post menopausal women.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • postmenopausal women, age 60-78 years
  • normal general laboratory tests
  • serum calcium >10.6 mg/dl (2.65 mmol/L ) or >0.3 mg/dl (0.075mmol/L) above upper limit of normal on 2 baseline tests,
  • 24-hour urine calcium < 300mg (7.5mmol) on two baseline tests,
  • Bone mineral density (BMD) measured by DEXA of the spine vertebrae L2-3 of 0.70-1.05 g/cm2

Exclusion criteria

  • no significant medical disorder known to affect calcium or bone metabolism- hypercalcemia, active renal stone disease ( more than 1 stone episode/ year) or more than 2 stone episodes in a lifetime, sarcoidosis
  • severe chronic illness, chronic renal failure ( serum creatinine >1.4mg/dl ,chronic heart failure,
  • any terminal illness
  • any history of cancer (except skin cancer) within the last 10 years,
  • uncontrolled diabetes with significant proteinuria or fasting blood sugar > 140mg/dl
  • alcoholism
  • prolonged hospitalization , extended immobilizations or arthritis that prevents normal physical activity, hemiplegia, previous hip fracture
  • no previous treatment with medication known to affect bone and calcium metabolism within the last year; chronic corticosteroid therapy > 10mg/day thiazides, taking long term bisphosphonates or had them for more than 3 months in the past year, parathyroid hormone or derivatives in the last year, estrogen therapy within the last 6 months, anticonvulsants such as phenytoin ,high dose phenobarbital
  • BMI > 45kg/m2

Treatment and study plan

doxercalciferol capsules, Hectorol®

Drug

doxercalciferol capsules given in escalating doses from 1mcg to 5mcg daily.If serum calcium is elevated at any dose then that dose is maintained long term for 24 months.The change in bone mineral density will be measured at baseline ,12 and 24 months

Matched Placebo (Capsules)

Drug

oral doses increased from 1 to 5mcg once daily until serum calcium is elevated and given for 2 years.The change in bone mineral density will be measured at baseline ,12 and 24 months

Primary outcomes

  1. change in spine and femur density over 2 years

    Time frame: Baseline, 6,12,18,24 months at study completion

    measurements every 6 months over 2 years

Secondary outcomes

  1. safety of doxercalciferol on serum and urine calcium excretion

    Time frame: From enrollment ,measurements at baseline, weeks 1,2,3,4,5,12 after first dose, then every 3 months until study completion at 24 months

    measurement of serum and 24 hour urine calcium

Other outcomes

  1. efficacy of doxerxalciferol in stimulating calcium absorption

    Time frame: Baseline , 6months,12 months

    radioactive calcium absorption Ca45

Sponsors and collaborators

Lead sponsor

Creighton University

Other

Registry information

Official study title

Efficacy and Safety of Doxercalciferol on Spinal and Femoral Density in Postmenopausal Osteopenic Women

Important dates

Study start
1989
Primary completion
1992
Study completion
1994
First posted
Jun 22, 2026
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.